Last reviewed 2026-05-20 · How we verify

Lovenox (Preservative Free) (ENOXAPARIN SODIUM)

Lovenox (Preservative Free) (generic name: ENOXAPARIN SODIUM) is a Low Molecular Weight Heparin Oligosaccharide drug developed by Sanofi. It is currently FDA-approved (first approved 1993) for Deep venous thrombosis, Myocardial infarction, Prevention of clot formation during haemodialysis.

Lovenox works by enhancing the activity of antithrombin-III to inhibit blood clotting.

Lovenox (Preservative Free) is an antithrombin-III activator, a type of oligosaccharide medication that belongs to the drug class of activators. It works by activating antithrombin-III, a protein that helps regulate blood clotting.

At a glance

Mechanism of action

Enoxaparin is low molecular weight heparin which has antithrombotic properties.

Approved indications

• Deep venous thrombosis
• Myocardial infarction
• Prevention of clot formation during haemodialysis
• Prevention of venous thromboembolism
• Pulmonary embolism
• Unstable angina

Boxed warnings

• WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity or spinal surgery Optimal timing between the administration of enoxaparin sodium injection and neuraxial procedures is not known Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis [see Warnings and Precautions (5.1) and Drug Interactions (7) ] . WARNING: SPINAL/EPIDURAL HEMATOMAS See full prescribing information for complete boxed warning. Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity or spinal surgery Optimal timing between the administration of enoxaparin sodium injection and neuraxial procedures is not known Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. ( 5.1 , 7 )

Common side effects

• Bleeding
• Injection site hematomas
• Hemorrhage
• Anemia
• Thrombocytopenia
• Elevation of serum aminotransferase
• Diarrhea
• Nausea
• Ecchymosis
• Fever
• Edema
• Dyspnea

Key clinical trials

• Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO (PHASE2)
• Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients (OPTI-TREX) (PHASE4)
• Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management (NA)
• A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty (PHASE3)
• Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction (NA)
• REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults (PHASE3)
• A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants (PHASE2)
• Impact Of Laparoscopic Sleeve Gastrectomy On Obesity-Related Comorbidities In Patients Over 65 Years (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Lovenox (Preservative Free) CI brief — competitive landscape report
• Lovenox (Preservative Free) updates RSS · CI watch RSS
• Sanofi portfolio CI

Frequently asked questions about Lovenox (Preservative Free)

Related

• Drug class: All Low Molecular Weight Heparin drugs
• Target: All drugs targeting Antithrombin-III
• Manufacturer: Sanofi — full pipeline
• Therapeutic area: All drugs in Cardiovascular
• Indication: Drugs for Deep venous thrombosis
• Indication: Drugs for Myocardial infarction
• Indication: Drugs for Prevention of clot formation during haemodialysis

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing